Hypothesis

Long‑term suppression of prostaglandin production with NSAIDs or opioids diminishes TRPV1‑mediated calcium entry, which in turn reduces AMPK‑ULK1‑dependent autophagy and impairs immune clearance of senescent cells. This loss of a prostaglandin‑TRPV1 damage‑surveillance conduit accelerates the accumulation of cellular damage, driving a faster biological aging trajectory.

Mechanistic Rationale

Prostaglandin E₂ (PGE₂) generated by COX‑1/2 enzymes sensitizes TRPV1 via EP1/IP receptors and PKC‑dependent phosphorylation [3]. Sensitized TRPV1 opens to allow Ca²⁺ influx, activating the CaMKKβ‑AMPK axis. Active AMPK phosphorylates ULK1 at Ser555, initiating the autophagy initiation complex [4]. Autophagy clears damaged mitochondria and protein aggregates, while AMPK also promotes FOXO‑mediated transcription of lysosomal genes, enhancing overall proteostasis.

In parallel, PGE₂ acting on EP2/EP4 receptors raises cAMP, activating PKA, which phosphorylates and activates ULK1 at Ser757, providing a second, prostaglandin‑dependent autophagy trigger [5]. Chronic NSAID or opioid use lowers PGE₂ levels, thereby attenuating both calcium‑AMPK and cAMP‑PKA inputs to ULK1.

Reduced autophagy leads to imperfect removal of senescent cells; senescent cells persist and secrete SASP factors that further drive tissue dysfunction [1][2]. The resulting increase in senescence burden correlates with epigenetic clocks and frailty indices, providing a mechanistic link between analgesic use and accelerated biological aging.

Testable Predictions

1. Individuals on chronic NSAID (>6 mo) or opioid therapy will show lower basal autophagic flux in peripheral blood mononuclear cells (PBMCs) compared with age‑matched controls, measured as decreased LC3‑II/LC3‑I ratio and increased p62 accumulation after lysosomal blockade.
2. The same cohort will exhibit higher circulating SASP biomarkers (IL‑6, IL‑8, MMP‑9) and increased p16^INK4a^ expression in PBMCs, indicative of greater senescent cell load.
3. Ex vivo PGE₂ supplementation of PBMCs from analgesic‑treated donors will rescue AMPK phosphorylation (Thr172) and ULK1 activation (Ser555/Ser757) and restore autophagic flux to control levels.
4. In a longitudinal observational study, higher analgesic exposure will predict a faster increase in epigenetic age acceleration (e.g., GrimAge) over 2‑year intervals, independent of baseline pain severity.

Experimental Approach

• Human cohort: Recruit 120 adults aged 50‑75, stratified into three groups (chronic NSAID, chronic opioid, analgesic‑free) matched for pain intensity (WOMAC/VAS) and comorbidities. Collect fasting blood at baseline and annually for 2 years.
• Autophagy assay: Isolate PBMCs, treat with bafilomycin A1 for 4 h to block lysosomal degradation, then immunoblot for LC3‑I/II and p62. Calculate flux as (LC3‑II + Baf) − LC3‑II − Baf.
• Senescence burden: Flow cytometry for p16^INK4a^ intracellular staining; ELISA for plasma IL‑6, IL‑8, MMP‑9.
• Rescue experiment: Incubate a subset of PBMCs from analgesic groups with 100 nM PGE₂ for 30 min before bafilomycin treatment; repeat autophagy immunoblots.
• Aging outcome: Perform Illumina EPIC array on DNA extracted from PBMCs; compute GrimAge acceleration.
• Statistical plan: Use mixed‑effects models to assess group differences over time, adjusting for age, sex, BMI, and baseline pain. Mediation analysis will test whether autophagy flux mediates the effect of analgesic exposure on GrimAge acceleration.

If the hypotheses are confirmed, they would reveal that pharmacologically silencing an ancient prostaglandin‑TRPV1 damage‑signaling system compromises cellular housekeeping pathways, turning a therapeutic intent into a driver of accelerated aging. Conversely, a null result would refute the notion that routine analgesic use impairs core longevity mechanisms, redirecting focus to other mediators of the observed mortality associations.